The abstract is read at the publisher; the summary is JClub's.
Immune checkpoint gene phenotypes in cutaneous melanoma stratify overall survival, with ICG-high linked to longer survival versus ICG-low (HR 0.34, 95% CI 0.22–0.51).
- Why it matters: Checkpoint inhibitor benefit varies across patients, and the field lacks transcriptomic tumor-immune phenotypes that connect immune programs, treatment remodeling, and prognosis in cutaneous melanoma.
- What they did: The study clustered 47 immune checkpoint genes in 472 TCGA-SKCM tumors and used Cox models adjusted for AJCC stage, age, and sex, then reanalyzed GSE91061 and GSE120575 single-cell data. It also measured CD274, CXCL10, and HLA-A after recombinant human IFN-γ (10 or 100 ng/mL) in melanoma cell lines.
- The result: ICG scores correlated with the CD8 T-cell signature (Spearman ρ = 0.828, P = 5.06×10^-120), paired on-treatment ICG scores increased (median change 0.115; P = 0.012), and immune-cell IFN-γ and IFN-β scores were higher in nonresponders (P = 1.29×10^-4 and P = 0.004).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.